ClinicalTrials.gg
Not yet recruitingNCT06646783Updated Oct 17, 2024

Phase IIT Trial of SNA014

An Early Phase 1 interventional study of [68Ga]Ga-NODAGA-SNA014 in Adenocarcinoma of the Stomach, Adenocarcinoma of GE Junction and Pancreatic Cancer Stage, sponsored by SmartNuclide Biopharma. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-10-17.

Sponsored by SmartNuclide Biopharma · Early Phase 1, Interventional, and Diagnostic

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 630 studies in Pancreatic Neoplasms with a site in China — 334 open to participants now, 360 under way, 30 of them phase 3. Pancreatic Neoplasms · China.

Planned enrollment
395th of 508
28 · median 58
Started
2024
with 107 others
Phase 1
111 of 630
62 open now
Primary completion
2025-10
later than 87 of 359 live
Registered
450th of 630
by date

Among the 630 studies in Pancreatic Neoplasms with a site in China, this one is the 395th largest by planned enrollment of the 508 interventional ones that give a count, is one of 108 that started in 2024, is one of 111 in phase 1, reaches primary completion later than 87 of the 359 other live ones, and was the 450th registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

334 of the 630 studies in Pancreatic Neoplasms with a site in China are open now. Recruiting first, the newest first:

329 more — sign in →

All 334 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 745 Pancreatic Neoplasms studies recruiting now, 478 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 630 studies in Pancreatic Neoplasms with a site in China, or all of them as a file.
02

Study summary

68Ga labeled Claudin 18.2 contrast agent combined with PET/CT for gastric or gastroesophageal junction

03

Conditions studied

  • Adenocarcinoma of the Stomach
  • Adenocarcinoma of GE Junction
  • Pancreatic Cancer Stage
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age range of 18 to 75 years old (including boundary values);
  • Individuals with behavioral capacity who voluntarily participate in this clinical study and sign an form (ICF);
  • Diagnosed G/GEJ adenocarcinoma and pancreatic cancer;
  • Gastroscopy/CT/MRI/PET-CT examination results within the past month (if any);
  • Pathological test results and Claudin18.2 immunohistochemistry results within the past year (if available).

Exclusion criteria

Exclusion Criteria:

  • Merge patients with other clearly diagnosed malignant tumors:
  • Uncontrolled severe infections or individuals with other serious illnesses;
  • Those with an expected survival period of less than or equal to three months;
  • Pregnant or lactating patients, as well as reproductive age patients who refuse to take appropriate measures during this trial;
  • investigators determine that patients who are not suitable to participate in this study;
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Early Phase 1
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    dose escalation

    subgroups mass does escalation

    Drug: [68Ga]Ga-NODAGA-SNA014

Interventions

  • Perform whole-body PET/CT scans on the subjects at 30 minutes (± 5 minutes), 60 minutes (± 10 minutes), 120 minutes (± 20 minutes), and 240 minutes (± 30 minutes) after administration. Among them, PET scanning can be performed on 1-2 subjects in a certain dose group or each dose group for 30-60 minutes. Among the four CT scans, one CT scan is a conventional low-dose CT scan (120mA), and the remaining three are extremely low-dose CT scans (10-20mA). The main researchers and nuclear medicine physicians can decide whether to change the subsequent image acquisition time and duration of the subjects based on the image information obtained from the enrolled subjects.

06

What researchers measure

Primary outcomes

  1. Biological distribution characteristics

    Evaluate the biological distribution characteristics of important organs in the subjects. * Draw the Volume of Interest (VOI) of the subject's vital organs and calculate the Percentage of Injected Activity (IA) of the vital organs * Using PMOD software, manually draw regions of interest (VOI) on PET/CT images of the liver, spleen, normal stomach, heart, bone marrow, kidneys, and other areas to obtain the cumulative radioactive activity of these regions. Divide the cumulative radioactive activity by the injection dose to obtain the percentage of injection activity (% IA).

    Time frame: 1week

  2. Safety tolerance characteristics

    AE/SAE/SUSAR

    Time frame: hrough study completion, an average of 1 year

Secondary outcomes

  1. Metabolic Dynamics Evaluation and Radiation Dose

    Detect the radiation dose of whole blood and serum of the subjects, and calculate the absorbed dose of important organs

    Time frame: 1 day

Other outcomes

  1. Exploring the targeting ability of CLDN18.2

    Correlation analysis between PET/CT imaging features of target lesions (SUVmax, SUV mean, target to body ratio, etc.) and CLDN18.2IHC expression level (if any)

    Time frame: 1month

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2024; primary completion for Oct 2025, 12 months later.

Of 171 industry-sponsored phase 1 interventional studies under Pancreatic Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 62. This study's planned 12 months is below that.

Counting every sponsor, half of 379 studies reached it within 45 months; a quarter within 32 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2024
First posted
Oct 17, 2024
StartEst.
Oct 20, 2024
Primary completionEst.
Oct 20, 2025
CompletionEst.
Nov 20, 2025
Last update
Oct 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06646783
Responsible party
Sponsor
First posted
Oct 17, 2024
Start date
Oct 20, 2024 (estimated)
Primary completion
Oct 20, 2025 (estimated)
Completion
Nov 20, 2025 (estimated)
Last update
Oct 17, 2024

Study contacts

Miao liyan Chief Pharmacist, doctorate
Contact
miaolysuzhou@163.com
0512-679-72858

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gallium-68

Start the discussion